CTOs on the Move

GlaxoSmithKline

www.gsk.com

 
We are a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization`s three priority diseases – HIV/AIDS, tuberculosis and malaria, we are very proud to have developed some of the leading global medicines in these fields. Our product portfolio also includes a range of consumer brands, many of which are household names around the world, including Sensodyne, Aquafresh, Horlicks, Panadol and Tums.
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.gsk.com
  • 5 Crescent Drive
    Philadelphia, PA USA 19112
  • Phone: 215.751.7160

Executives

Name Title Contact Details
Delfim Martins
 VP Cyber Defense Profile
Lisa Ackerman
 Deputy CISO, Cyber Security Strategy and Solutions Profile
Jeff Wrona
 Senior Director, Security Infrastructure, Global Security Operations, GSK Profile
Tara Jaques
 Sr. Director, Security Posture and Assurance Profile
Jon Frampton
 Director, Data Security Services Profile

Similar Companies

PHC Holdings

This is the website of PHC Holdings Corporation, which is a global innovator in healthcare solutions.

Acclaim Physician Group

Envision Communications

Envision Communications is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmakon Pharmaceuticals

Pharmakon Pharmaceuticals is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.